Investors
Investors
Creating value for stakeholders
We are an established, commercial-stage diagnostics company.
We are an established, commercial-stage diagnostics company with over 30 years’ experience of manufacturing and supplying the conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market.


Our proprietary technology platform, MosaiQ, is continually been developed and enhanced to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology that significantly reduces the cost of blood grouping in both donor and patient-testing environments.

Investors

4:00 PM EDT • Apr 8, 2020
QTNT
5.35USD
-0.56%
Contact
Peter Buhler
Chief Financial Officer
+41 22 545 52 26
3 Months
6 Months
12 Months
USD

Events & presentations

Quotient Limited to Host Investor Information Conference Call and Live Webcast
Quotient Limited Fiscal Third Quarter 2020 Financial Results

Press releases

Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development
Quotient Limited to Host Investor Information Conference Call and Live Webcast
Quotient Limited Reports Concordance Data from Extended Serological Disease Screening Benchmark Study
Financials & filings

Get up-to-date information about our Company’s financials.

Corporate governance

Retrieve corporate policy documents, committee charters, and more. 

Stock information

Follow our latest stock quote and historical information.

Our reagents by Quotient
Alba by Quotient. Experience. Expertise. Value.
These are just some of the qualities that set us apart from the competition. You can have peace of mind using our products, which have been time-tested for more than 30 years.